Evidence map›Paper›PMID 25909600›Full record

ArticlePloS one2015

Cell, isoform, and environment factors shape gradients and modulate chemotaxis.

S Laura Chang, Stephen P Cavnar, Shuichi Takayama, Gary D Luker, Jennifer J Linderman

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Engineering Approaches to Study Cellular Decision Making.Annual review of biomedical engineering · 2018
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

S Laura ChangDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
Stephen P CavnarDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
Shuichi TakayamaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Macromolecular Science and Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
Gary D LukerDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America.
Jennifer J LindermanDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America.
Michigan United · USUniversity of Michigan–Ann Arbor · US

Funding

Small Animal Imaging CoreP50CA093990 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSS, BRIAN D. · 2002 to 2012
$19.0M
Proteogenomics of Cancer Training ProgramT32CA140044 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, ARVIND, SARTOR, MAUREEN AGNES · 2010 to 2024
$3.9M
Targeted Multi-Spectral Dual Axes Confocal Imaging of In Vivo Molecular ExpressioR01CA142750 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KURABAYASHI, KATSUO, LUKER, GARY D · 2010 to 2014
$2.4M
A multi-scale model to predict outcomes of immunomodulation and drug therapy duriR01EB012579 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLYNN, JOANNE L., KIRSCHNER, DENISE E · 2011 to 2014
$2.3M
Molecular Imaging of Chemokine Receptor SignalingR01CA136553 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D · 2009 to 2013
$1.5M
Microfluidic Analysis of Oscillatory Signaling Pathways Using Phase LockingR01GM096040 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAKAYAMA, SHUICHI · 2011 to 2014
$1.1M
A Novel High Throughput Tumor Spheroid MicrotechnologyR21CA182333 · NCI · UNIVERSITY OF AKRON · PI LUKER, GARY D, TAVANA, HOSSEIN · 2013 to 2014
$503k
NCI NIH HHS P50 CA093990NCI NIH HHS P50CA093990NCI NIH HHS R01 CA136553NCI NIH HHS R01CA136553NCI NIH HHS R01 CA142750NCI NIH HHS R01CA142750NCI NIH HHS R21 CA182333NCI NIH HHS R21CA182333NCI NIH HHS T32 CA140044NIBIB NIH HHS EB012579NIBIB NIH HHS R01 EB012579NIGMS NIH HHS GM096040NIGMS NIH HHS R01 GM096040
6 · The paper itself

Abstract

Chemokine gradient formation requires multiple processes that include ligand secretion and diffusion, receptor binding and internalization, and immobilization of ligand to surfaces. To understand how these events dynamically shape gradients and influence ensuing cell chemotaxis, we built a multi-scale hybrid agent-based model linking gradient formation, cell responses, and receptor-level information. The CXCL12/CXCR4/CXCR7 signaling axis is highly implicated in metastasis of many cancers. We model CXCL12 gradient formation as it is impacted by CXCR4 and CXCR7, with particular focus on the three most highly expressed isoforms of CXCL12. We trained and validated our model using data from an in vitro microfluidic source-sink device. Our simulations demonstrate how isoform differences on the molecular level affect gradient formation and cell responses. We determine that ligand properties specific to CXCL12 isoforms (binding to the migration surface and to CXCR4) significantly impact migration and explain differences in in vitro chemotaxis data. We extend our model to analyze CXCL12 gradient formation in a tumor environment and find that short distance, steep gradients characteristic of the CXCL12-γ isoform are effective at driving chemotaxis. We highlight the importance of CXCL12-γ in cancer cell migration: its high effective affinity for both extracellular surface sites and CXCR4 strongly promote CXCR4+ cell migration. CXCL12-γ is also more difficult to inhibit, and we predict that co-inhibition of CXCR4 and CXCR7 is necessary to effectively hinder CXCL12-γ-induced migration. These findings support the growing importance of understanding differences in protein isoforms, and in particular their implications for cancer treatment.

Indexed as

AlgorithmsCell Line, TumorCell MovementChemokine CXCL12ChemotaxisHumansLigandsModels, BiologicalProtein BindingProtein IsoformsReceptors, CXCRReceptors, ImmunologicReproducibility of ResultsACKR3 protein, humanChemokine CXCL12LigandsProtein IsoformsReceptors, CXCRReceptors, Immunologic

Identifiers

PMID25909600
PMCPMC4409393
OpenAlexW1997717468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.